NousCom CEO Outlines Cancer Vaccine Strategy
Executive Summary
NousCom CEO and co-founder Alfredo Nicosia speaks to Scrip senior editor Lucie Ellis during BIO-Europe, a partnering meeting held in berlin Nov. 6-8, about the company's recent series B financing.
You may also be interested in...
Inivata's John Beeler On The Future Of Liquid Biopsies
John Beeler, vice-president of corporate and business development at Inivata, speaks to Scrip's Lucie Ellis about how the company's technology is aligned with the current genomic medicine revolution facing the pharmaceutical industry.
NousCom Raises €42m For Novel Cancer Vaccines
European biotech NousCom is making ready two multi-neoantigen containing vaccines that with a new round of VC funding should enter clinical studies in 2018, and that it hopes to combine with checkpoint inhibitors.
Finding Value Left On The Shelf: Karuna Case Study
PureTech’s gamble to take an older Eli Lilly drug off the shelf to redevelop in a new indication paid off. The company aims to replicate this 'Karuna model' in the near future.